Diphenhydramine hydrochlorideCAS# 147-24-0 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 147-24-0 | SDF | Download SDF |
PubChem ID | 8980 | Appearance | Powder |
Formula | C17H22ClNO | M.Wt | 291.8 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | DMSO : 100 mg/mL (342.68 mM; Need ultrasonic) H2O : 100 mg/mL (342.68 mM; Need ultrasonic) | ||
Chemical Name | 2-benzhydryloxy-N,N-dimethylethanamine;hydrochloride | ||
SMILES | CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2.Cl | ||
Standard InChIKey | PCHPORCSPXIHLZ-UHFFFAOYSA-N | ||
Standard InChI | InChI=1S/C17H21NO.ClH/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16;/h3-12,17H,13-14H2,1-2H3;1H | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | H1 receptor antagonist. Antihistamine. |
Diphenhydramine hydrochloride Dilution Calculator
Diphenhydramine hydrochloride Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.427 mL | 17.135 mL | 34.27 mL | 68.5401 mL | 85.6751 mL |
5 mM | 0.6854 mL | 3.427 mL | 6.854 mL | 13.708 mL | 17.135 mL |
10 mM | 0.3427 mL | 1.7135 mL | 3.427 mL | 6.854 mL | 8.5675 mL |
50 mM | 0.0685 mL | 0.3427 mL | 0.6854 mL | 1.3708 mL | 1.7135 mL |
100 mM | 0.0343 mL | 0.1714 mL | 0.3427 mL | 0.6854 mL | 0.8568 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- QL47
Catalog No.:BCC3920
CAS No.:1469988-75-7
- Atglistatin
Catalog No.:BCC5104
CAS No.:1469924-27-3
- Y-27632 dihydrochloride
Catalog No.:BCC1273
CAS No.:129830-38-2
- Y-27632
Catalog No.:BCC4301
CAS No.:146986-50-7
- Fmoc-Lys(Aloc)-OH
Catalog No.:BCC3515
CAS No.:146982-27-6
- Fmoc-Asp(OAll)-OH
Catalog No.:BCC3089
CAS No.:146982-24-3
- Codaphniphylline
Catalog No.:BCN1652
CAS No.:14694-15-6
- Ziprasidone
Catalog No.:BCC2071
CAS No.:146939-27-7
- K-Ras(G12C) inhibitor 12
Catalog No.:BCC5562
CAS No.:1469337-95-8
- K-Ras(G12C) inhibitor 9
Catalog No.:BCC6500
CAS No.:1469337-91-4
- 1,2-Diacetoxy-4,7,8-trihydroxy-3-(4-hydroxyphenyl)dibenzofuran
Catalog No.:BCN7691
CAS No.:146905-24-0
- Triptobenzene H
Catalog No.:BCN6784
CAS No.:146900-55-2
- DL-Arabinose
Catalog No.:BCN8541
CAS No.:147-81-9
- Proline
Catalog No.:BCN1656
CAS No.:147-85-3
- Cytarabine
Catalog No.:BCC3759
CAS No.:147-94-4
- 3'-O-Demethylarctigenin
Catalog No.:BCN3544
CAS No.:147022-95-5
- Menthyl-5-(4-amino-2-oxo-2H-pyrimidin-1-yl)-[1,3]oxathiolane-2-carboxylic acid
Catalog No.:BCC9019
CAS No.:147027-10-9
- MK591
Catalog No.:BCC1766
CAS No.:147030-01-1
- Cyclo(Phe-Pro)
Catalog No.:BCN2416
CAS No.:14705-60-3
- Rocaglaol
Catalog No.:BCN1653
CAS No.:147059-46-9
- Trovafloxacin mesylate
Catalog No.:BCC3931
CAS No.:147059-75-4
- Alcaftadine
Catalog No.:BCC5260
CAS No.:147084-10-4
- 5,6-Dihydro-6-methyl-4H-thieno[2,3-b]thiopyran-4-one
Catalog No.:BCC8722
CAS No.:147086-79-1
- Rosuvastatin Calcium
Catalog No.:BCC3853
CAS No.:147098-20-2
Donepezil: an unusual therapy for acute diphenhydramine overdose.[Pubmed:30898954]
BMJ Case Rep. 2019 Mar 20;12(3). pii: 12/3/e226836.
An elderly man presented with the history of Diphenhydramine hydrochloride overdose as a suicidal attempt. At presentation, he was in an acute confusional state with several anticholinergic features and had to be managed in intensive care unit. As an antidote for Diphenhydramine hydrochloride, donepezil was used instead of physostigmine due to the unavailability of physostigmine in Bangladesh. The patient improved within the next 24 hours; his level of consciousness improved and the anticholinergic features regressed.
Block of potassium currents in guinea pig ventricular myocytes and lengthening of cardiac repolarization in man by the histamine H1 receptor antagonist diphenhydramine.[Pubmed:9918600]
J Pharmacol Exp Ther. 1999 Feb;288(2):858-65.
Treatment with second generation histamine H1 receptor antagonists has been associated with lengthening of the Q-T interval and proarrhythmia. Similarly, lengthening of the Q-T interval has been reported in patients after overdosing with diphenhydramine (DPH), a first generation agent. Therefore, our study was designed 1) to assess effects of DPH on cardiac repolarization and 2) to characterize effects of the drug on major voltage-dependent cardiac K+ currents. First, we noticed that oral administration of DPH at usual dosages to healthy volunteers or to patients (prior to angioplasty) was associated with prolongation of the Q-Tc interval. Although this effect was modest in most individuals, Q-Tc was increased more than 20 ms in 7 of 20 patients. Second, we noticed that exposure of isolated guinea pig hearts to DPH 10(-5) M caused a lengthening of monophasic action potential duration. This effect was potentiated by the combined perfusion of other K+ channel blockers such as indapamide. Finally, experiments performed with the patch-clamp technique demonstrated unequivocal block of the rapid component of the delayed rectifier (IKr) by DPH; however, IC50 determined for block of IKr (3 x 10(-5) M) is approximately 40-fold greater than plasma concentrations of the drug measured at usual dosages (7 x 10(-7) M). Consequently, in agreement with the long-term clinical use of the drug, prolongation of cardiac repolarization should be minimal in most patients at usual dosages but may be observed with overdosing. Nevertheless, caution remains since excessive lengthening of cardiac repolarization may occur after administration of DPH with other drugs due to 1) concomitant block of other ionic currents or 2) pharmacokinetic interactions leading to toxic concentrations of DPH.